![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
MTX110 (panobinostat) is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor), which is investigated for the treatment of Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas.
Lead Product(s): Panobinostat lactate,Gadolinium
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Luca Szalontay
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023